; (2) by striking 483.3(s)(5) and inserting 438.3(s)(5) ; and (3) by adding at the end the following: Such a managed care entity shall not be considered to be in compliance with the requirement of such section 438.3(s)(5) that the entity provide a detailed description of its drug utilization review activities unless the entity includes a description of the prospective drug review activities described in paragraph (2)(A) of section 1927(g) and the activities listed in paragraph (3)(C) of section 1927(g), makes the underlying drug utilization review data available to the State and the Secretary, and provides such other information as deemed appropriate by the Secretary. . (c) Development of national standards for Medicaid drug use review The Secretary of Health and Human Services may promulgate regulations or guidance establishing national standards for Medicaid drug use review programs under section 1927(g) of the Social Security Act ( 42 U.S.C. 1396r–8 ) and drug utilization review activities and requirements under section 1932(i) of such Act ( 42 U.S.C. 1396u–2(i) ), for the purpose of aligning review criteria for prospective and retrospective drug use review across all State Medicaid programs. (d) CMS guidance Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services shall issue guidance— (1) outlining steps that States must take to come into compliance with statutory and regulatory requirements for prospective and retrospective drug use review under section 1927(g) of the Social Security Act ( 42 U.S.C. 1396r–8(g) ) and drug utilization review activities and requirements under section 1932(i) of such Act ( 42 U.S.C. 1396u–2(i) ) (including with respect to requirements that were in effect before the date of enactment of this Act)